Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,585,896
  • Shares Outstanding, K 173,322
  • Annual Sales, $ 10,010 K
  • Annual Income, $ -337,710 K
  • EBIT $ -343 M
  • EBITDA $ -350 M
  • 60-Month Beta 1.59
  • Price/Sales 186.30
  • Price/Cash Flow N/A
  • Price/Book 2.55

Options Overview Details

View History
  • Implied Volatility 345.89% (+49.23%)
  • Historical Volatility 73.15%
  • IV Percentile 77%
  • IV Rank 42.35%
  • IV High 759.75% on 09/12/25
  • IV Low 41.91% on 04/04/25
  • Expected Move (DTE 8) 1.33 (15.33%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 148
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 3,371
  • Open Int (30-Day) 3,846
  • Expected Range 7.32 to 9.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 6
  • High Estimate -0.20
  • Low Estimate -0.44
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +15.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.01 +20.04%
on 01/20/26
9.28 -9.32%
on 02/12/26
+0.61 (+7.88%)
since 01/12/26
3-Month
6.04 +39.32%
on 11/13/25
9.28 -9.32%
on 02/12/26
+2.24 (+36.39%)
since 11/12/25
52-Week
1.77 +375.42%
on 04/07/25
9.28 -9.32%
on 02/12/26
+4.65 (+123.80%)
since 02/12/25

Most Recent Stories

More News
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 8.51 (-6.99%)
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

Designation supported by robust clinical  data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib...

RLAY : 8.51 (-6.99%)
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with...

RLAY : 8.51 (-6.99%)
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated  breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercialization...

RLAY : 8.51 (-6.99%)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 8.51 (-6.99%)
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge...

RLAY : 8.51 (-6.99%)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 8.51 (-6.99%)
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase...

RLAY : 8.51 (-6.99%)
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge...

RLAY : 8.51 (-6.99%)
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

Recursion Pharmaceuticals RXRX faced a significant setback in May 2025 after announcing the discontinuation of three key drug candidates — REC-994, REC-2282, and REC-3964 — as part of its broader strategic...

RLAY : 8.51 (-6.99%)
SDGR : 11.74 (-2.00%)
RXRX : 3.53 (-4.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 10.22
2nd Resistance Point 9.69
1st Resistance Point 9.42
Last Price 8.51
1st Support Level 8.62
2nd Support Level 8.09
3rd Support Level 7.82

See More

52-Week High 9.28
Last Price 8.51
Fibonacci 61.8% 6.41
Fibonacci 50% 5.52
Fibonacci 38.2% 4.64
52-Week Low 1.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar